Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Takeda Pharmaceutical Ltd ADR
(NY:
TAK
)
12.67
-0.50 (-3.80%)
Official Closing Price
Updated: 7:00 PM EDT, Jun 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Takeda Pharmaceutical Ltd ADR
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Phathom Pharma's Vonoprazan Commercial Preparation Update At Needham Healthcare Conference
April 13, 2022
Via
Benzinga
The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More
April 12, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Monday Markets News
March 28, 2022
Japanese Takeda TAK shares failed to thrive after its edema prevention drug was approved.
Via
Talk Markets
Takeda's Angioedema Drug Shows Promising Action Against COVID-19 Infection
March 08, 2022
Takeda Pharmaceutical Co Ltd's (NYSE: TAK) Firazyr (icatibant), used to treat a blood vessel condition called angioedema, has shown promise as a treatment for COVID...
Via
Benzinga
FDA Approves Takeda's Vonvendi As Prophylactic Treatment In Bleeding Disorder
January 31, 2022
The
Via
Benzinga
Roche And AstraZeneca Settle Ultomiris Patent Lawsuit
February 22, 2022
Roche Holdings AG (OTC: RHHBY) has decided to close out a patent infringement lawsuit against AstraZeneca plc (NASDAQ: AZN), centering around the latter's newly...
Via
Benzinga
Takeda Inks $2B Gene Therapy Pact With Code Biotherapeutics
February 22, 2022
Takeda Pharmaceutical Co Ltd (NYSE: TAK) has signed up for a gene therapy pact, encoding a $2 billion biobucks deal with Code Biotherapeutics across four...
Via
Benzinga
Real-World Analysis Show Takeda's Alofisel Clinical Remission Rate At Six-Months
February 18, 2022
Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced the first six-month interim analysis results from INSPIRE study evaluating the Real-World Effectiveness and Safety of...
Via
Benzinga
The Best Russell 2000 Stocks to Buy Before they Rebound
February 15, 2022
Some of the best stocks in the market are among the best Russell 2000 stocks to buy. Here's a list of a few of those choices.
Via
InvestorPlace
Why Are Seagen Shares Sinking Today?
February 10, 2022
Seagen Inc (NASDAQ: SGEN) reported Q4 revenues
Via
Benzinga
Take a Leap Into Novavax Stock After Vaccine Sales Start
February 08, 2022
Novavax is worth speculating on at current levels. NVAX stock has fallen below the $100 mark ahead of its global Covid-19 vaccine launch.
Via
InvestorPlace
A News Blizzard
February 04, 2022
Markets are still down despite very encouraging news in January when 467,00 new hires got jobs.
Via
Talk Markets
Worldwide Adoption of Novavax Vaccines Makes It a Winner
January 21, 2022
Novavax can still generate billions of dollars of revenue per year from its shot, making NVAX stock quite attractive at its current levels.
Via
InvestorPlace
More Serious Matters
January 14, 2022
Wall Street fell on new worries about inflation and a drop in retail sales levels.
Via
Talk Markets
Denali Stock Tumbles; Why Biogen Isn't The Only Alzheimer's Play Under Pressure
January 13, 2022
Denali Therapeutics is under pressure after the FDA put its study on hold.
Via
Investor's Business Daily
Interest Rate Hikes And Stocks
January 12, 2022
Abnormal flooding in northwest Brazil has blocked iron ore mining which resulted in a jump in the price of ore.
Via
Talk Markets
Post-Fed Thursday
January 06, 2022
Companies earning in dollars but incorporated abroad and paying dividends in other currencies were big gainers today.
Via
Talk Markets
FDA Rejects Takeda's Eosinophilic Esophagitis Candidate, Asks For Additional Study
December 22, 2021
Takeda Pharmaceutical Co Ltd (NYSE: TAK) received a Complete Response Letter (CRL) from the FDA for its marketing application for TAK-721 (budesonide oral...
Via
Benzinga
The Daily Biotech Pulse: Allakos Slips Negative Late-Stage Data, Pfizer & Merck Announce Fresh COVID Pill Deal With UK, Regulatory Setback For Takeda
December 22, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Allakos's Lirentelimab Flunks Late-Stage Studies In Patients With...
Via
Benzinga
The Daily Biotech Pulse: Calliditas Snags FDA Nod, Novartis to Buy Back $15B In Shares, Valneva Touts Vaccine Data, Immix, Bionomics Debut On Wall Street
December 16, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Calliditas Gets Conditional Approval For Kidney Inflammation Disease Drug...
Via
Benzinga
Novavax Files For Approval Of Its COVID-19 Vaccine In Japan
December 16, 2021
Novavax Inc (NASDAQ: NVAX) has submitted a marketing application in Japan seeking approval for its COVID-19 vaccine by its partner Takeda Pharmaceutical Co Ltd...
Via
Benzinga
3 Stocks That Can Make You Rich in Just a Few Years
December 14, 2021
Investing in the most popular stocks on the Street won't make investors rich in a few years. To accomplish that goal, a contrarian spirit is needed.
Via
InvestorPlace
Comparing Data: Sanofi Vs. Johnson & Johnson Multiple Myeloma Therapies In Newly Diagnosed Patients
December 13, 2021
Sanofi SA (NASDAQ: SNY) and Johnson & Johnson (NYSE: JNJ) posted new data from their myeloma therapies, Sarclisa and Darzalex, respectively. Data were shared at...
Via
Benzinga
7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts
December 07, 2021
These seven drug stocks, a mix of growth, value, and moonshot plays, each stand to see big moves in the next twelve months.
Via
InvestorPlace
Exposures
COVID-19
Happy December
December 01, 2021
Inflation levels this year will almost certainly lower growth in 2022 because of inflation this year in everything from house prices....to stock prices.
Via
Talk Markets
The Week Ahead In Biotech (Nov. 28-Dec. 4): FDA Decisions For VBI Vaccines, & More
November 28, 2021
Biotech stocks advanced in the week ending Nov. 26, as a late-week surge on the back of news about a new COVID-19 variant helped mitigate the losses notched earlier in the holiday-shortened week.
Via
Talk Markets
Exposures
COVID-19
Product Safety
The Week Ahead In Biotech (Nov. 28-Dec. 4): FDA Decisions For VBI Vaccines, BeyondSpring, CTI Biopharma And Merck Take The Spotlight In A Light Calendar Week
November 28, 2021
Biotech stocks advanced in the week ending Nov. 26, as a late-week surge on the back of news about a new COVID-19 variant, named Omicron, helped mitigate the losses...
Via
Benzinga
Exposures
COVID-19
Product Safety
The Daily Biotech Pulse: Kura's Blood Cancer Drug Study Gets Partial Clinical Hold, Takeda FDA Nod, Puma Breast Cancer Treatment Gets Patent Extension
November 24, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Puma Biotech Announces Receipt Of Patent Extension For Breast Cancer Drug By...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Takeda's Maribavir Scores FDA Approval For Post-Transplant CMV Infection
November 24, 2021
The FDA has approved Takeda Pharmaceutical Co Ltd's (NYSE: TAK) Livtencity (maribavir) for a common type of viral infection occurring in patients after...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: Arrowhead Out-Licenses NASH Drug, Tonix Touts COVID-19 Treatment Data, Aadi Jumps On FDA Nod For Rare Tumor Drug
November 23, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Synlogic Presents Positive Phase 2 Data For Synthetic Biologic Treatment In...
Via
Benzinga
Exposures
COVID-19
Product Safety
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.